Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REC 2282

Drug Profile

REC 2282

Alternative Names: AR-42; NSC-D736012; OSU-HDAC42; REC-2282

Latest Information Update: 04 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ohio State University Research Foundation
  • Developer Arno Therapeutics; Celgene Corporation; Ohio State University Comprehensive Cancer Center; Recursion Pharmaceuticals; Virginia Commonwealth University
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Meningioma; Neurilemmoma; Neurofibromatosis 2
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Neurofibromatosis 2
  • No development reported Acute myeloid leukaemia
  • Discontinued Bladder cancer; Chronic lymphocytic leukaemia; Lymphoma; Meningioma; Multiple myeloma; Neurilemmoma; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 04 May 2023 REC 2282 receives Orphan Drug status for Neurofibromatosis 2 in USA, prior to May 2203
  • 14 Apr 2023 Pharmacodynamics data from a preclinical trial in human hepatocellular carcinoma presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 14 Apr 2022 Phase-II/III clinical trials in Neurofibromatosis 2 (In adolescents, In adults, In children, In the elderly) in USA (PO) (NCT05130866)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top